Table 1 Population baseline characteristics
From: Use of Sacubitril/valsartan in patients with cardio toxicity and heart failure due to chemotherapy
Characteristic (n = 28) | Mean ± SD or n (%) |
|---|---|
Age (years) | 56.2 ± 13.4 |
Females | 25 (89.3%) |
BP | 14 (50%) |
Smoker | 12 (42.86%) |
Hypercholesterolemia | 10 (35.71%) |
Diabetes Mellitus | 8 (28.57%) |
History of ischemic cardiac disease | 2 (7.14%) |
Left Breast Cancer | 18 (64.3%) |
Radiotherapy | 9 (32.1%) |
Ejection fraction (%) | 26.68 (5.35) |
Creatinine (mg/dl) | 1.31 ± 0.16 |
NYHA functional classification | |
I | 0 (0%) |
II | 0 (0%) |
III | 22 (78.6%) |
IV | 6 (21.4%) |
Chemotherapy | |
Doxorubicin | 23 (82.1%) |
Cyclophosphamide | 23 (82.1%) |
Docetaxel | 3 (10.7%) |
Trastuzumab | 8 (28.6%) |
Pertuzumab | 4 (14.3%) |
Days since chemotherapy started | 183.6 ± 95.4 |
Heart Failure treatment at enrollment | |
Beta Blockers | 26 (92,85%) |
ACEI | 12 (42.85%) |
ARB | 13 (46.43%) |
Digitalis | 9 (32.14%) |
Mineralocorticoids antagonist | 18 (64.28%) |
Diuretics | 20 (71.43%) |
ICD | 3 (10.71%) |
CRT-D | 2 (7.14%) |
Heart transplant | 1 (3.6%) |